Jupiter Endovascular, Inc., a medical tech innovator specializing in advanced endovascular procedures through Endoportal Control™, has received FDA approval for its Investigational Device Exemption application. This approval clears the way for the SPIRARE II U.S. pivotal study (NCT06576427) to advance,…
CharmHealth, a leader in healthcare technology solutions, has unveiled the winners of its 2024 Innovation Challenge. Entering its fourth year, the challenge aims to discover groundbreaking ideas poised to transform healthcare systems and processes. This year’s CharmHealth Innovation Challenge saw…
Renata Medical has announced that the U.S. Food and Drug Administration (FDA) has approved its innovative Minima Growth Stent, designed specifically for neonates, infants, and young children. This unique stent is engineered to be re-expanded as the child grows, offering…
Applied Statistics & Management Inc. (ASM), a top provider of medical staff credentialing and privileging solutions, has announced the retirement of its founder, President, and CEO, Trung Phan. Trung Phan will step down from his role on August 30, 2024,…
RebrAIn, a leader in precision neuro-surgery platforms, has secured its second FDA 510(k) clearance for its OptimMRI software. The latest version includes a machine learning model designed to aid in targeting the infero-lateral part of the VIM for lesioning techniques…
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible) announced that its AI-powered diagnostic tool, eyonis™ LCS, met the primary and all secondary endpoints in the REALITY study, the first of two pivotal trials required for marketing approval in the U.S. and…
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO: 4118) has opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido, marking its seventh domestic business location and the first new site in 54 years. An opening ceremony…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented at…
Novotech, a global full-service clinical Contract Research Organization (CRO), is pleased to announce its renewal as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) for 2024. This accolade highlights Novotech’s ongoing dedication to maintaining an…
Allurion Technologies, Inc. (NYSE: ALUR) has announced new study results showing an average weight reduction of 10.5% at four months, improving to 13.7% at one year with the Allurion Program. This data highlights that not only can weight loss be…
